Towards a new combination therapy for tuberculosis with next generation benzothiazinones

The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo-enzyme DprE1, decaprenylphosphoryl-beta-D-ribose 2-epimerase. Here, we synthesized a new series of piperazine-containing benzothiazinones (PBTZ) and show that, like BTZ043, the preclinical c...

Descripción completa

Detalles Bibliográficos
Autores principales: Makarov, Vadim, Lechartier, Benoit, Zhang, Ming, Neres, João, Sar, Astrid M, Raadsen, Susanne A, Hartkoorn, Ruben C, Ryabova, Olga B, Vocat, Anthony, Decosterd, Laurent A, Widmer, Nicolas, Buclin, Thierry, Bitter, Wilbert, Andries, Koen, Pojer, Florence, Dyson, Paul J, Cole, Stewart T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958311/
https://www.ncbi.nlm.nih.gov/pubmed/24500695
http://dx.doi.org/10.1002/emmm.201303575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958311/
https://www.ncbi.nlm.nih.gov/pubmed/24500695
http://dx.doi.org/10.1002/emmm.201303575

Ejemplares similares